Loading…
Avience Biomedicals (AVIENCE)₹249.95−2.00%Medical Equipment & Supplies
In the Mar 2026 quarter (consolidated), Avience Biomedicals reported sales of ₹25.73 Cr, up 4.9% from Mar 2025, and net profit of ₹4.23 Cr, down 1.4% year on year. For the year to Mar 2026, sales were ₹52.59 Cr and net profit ₹8.78 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 24.53 | 26.87 | 25.73 |
| Expenses | 17.93 | 19.63 | 18.05 |
| Operating Profit | 6.63 | 7.27 | 7.72 |
| OPM % | 27.0% | 27.1% | 30.0% |
| Other Income | 0.47 | 0.07 | 0.24 |
| Interest | 0.70 | 0.66 | 0.90 |
| Depreciation | 0.49 | 0.57 | 0.67 |
| Profit before tax | 5.89 | 6.09 | 6.36 |
| Tax % | 27.6% | 25.7% | 33.8% |
| Net Profit | 4.29 | 4.55 | 4.23 |
| EPS (Rs) | 10.58 | 11.25 | 10.46 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 23.88 | 45.03 | 52.59 |
| Expenses | 19.72 | 33.53 | 37.68 |
| Operating Profit | 4.19 | 11.56 | 15.00 |
| OPM % | 17.6% | 25.7% | 28.5% |
| Other Income | 0.42 | 0.59 | 0.30 |
| Interest | 0.95 | 1.46 | 1.55 |
| Depreciation | 0.63 | 0.89 | 1.23 |
| Profit before tax | 3.02 | 9.76 | 12.46 |
| Tax % | 28.7% | 27.3% | 29.8% |
| Exceptional items | 0.00 | −0.07 | 0.00 |
| Net Profit | 2.17 | 7.13 | 8.78 |
| EPS (Rs) | 6.57 | 17.59 | 21.68 |
| Dividend payout % | 0.0% | 0.0% | 0.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 3.29 | 4.04 | 4.04 |
| Reserves | 2.93 | 18.61 | 27.37 |
| Borrowings | 15.12 | 22.16 | 28.93 |
| Other Liabilities | 13.20 | 11.66 | 17.67 |
| Total Liabilities | 34.54 | 56.47 | 78.01 |
| Fixed Assets | 10.23 | 13.07 | 16.02 |
| CWIP | 0.02 | 4.61 | 12.84 |
| Investments | 0.02 | 0.02 | 0.02 |
| Other Assets | 24.27 | 38.77 | 49.13 |
| Inventories | 12.39 | 13.06 | 17.16 |
| Trade receivables | 8.11 | 17.27 | 21.06 |
| Cash & equivalents | 0.35 | 4.93 | 2.92 |
| Total Assets | 34.54 | 56.47 | 78.01 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | 1.03 | 3.38 | 2.79 |
| Cash from investing activity | −3.91 | −9.56 | −9.05 |
| Cash from financing activity | 2.92 | 10.20 | 3.06 |
| Net cash flow | 0.04 | 4.04 | −3.18 |
| Capex | 3.87 | 9.28 | 9.30 |
| Free cash flow | −2.80 | −5.87 | −6.42 |
| CFO / OP % | 29.1% | 36.1% | 35.1% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 125 | 141 | 147 |
| Inventory days | 291 | 177 | 219 |
| Days payable | 130 | 98 | 120 |
| Cash conversion cycle | 284 | 218 | 244 |
| Working capital days | 28 | 69 | 73 |
| ROCE % | — | 34.2% | 26.6% |
For the Mar 2026 quarter, Avience Biomedicals reported sales of ₹25.73 Cr, up 4.9% year on year and net profit of ₹4.23 Cr, down 1.4% year on year. The operating margin was 30.0%.
Avience Biomedicals' sales for the year to Mar 2026 were ₹52.59 Cr.
Net profit for the year to Mar 2026 was ₹8.78 Cr. Earnings per share over the same trailing period were ₹21.68.
Avience Biomedicals reported borrowings of ₹28.93 Cr at Mar 2026, against cash and equivalents of ₹2.92 Cr.
Cash from operations was ₹2.79 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹6.42 Cr.